Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tadalafil,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Qilu Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis®
Details : Cialis®, and the generic equivalent Tadalafil, is in a class of medications called phosphodiesterase (PDE) inhibitors. Tadalafil is used to treat erectile dysfunction and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate).
Product Name : Tadalafil-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 05, 2021
Lead Product(s) : Tadalafil,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Qilu Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ibuprofen,Inapplicable
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : AiPing Pharmaceutical Inc
Deal Size : Undisclosed
Deal Type : Agreement
ECI Pharmaceuticals LLC Enters into Exclusive U.S. Distribution Agreement for Ibuprofen
Details : According to IQVIA data for the 12 months ended December 2020, total U.S. generic sales of Ibuprofen tablets 400 mg, 600 mg, 800 mg was approximately $110 million. Generic Folic Acid tablets 1 mg were approximately $20 million for the same period.
Product Name : Ibuprofen-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 23, 2021
Lead Product(s) : Ibuprofen,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : AiPing Pharmaceutical Inc
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
